266 related articles for article (PubMed ID: 14604454)
1. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Hollander E; Baldini Rossi N; Sood E; Pallanti S
Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
[TBL] [Abstract][Full Text] [Related]
2. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
4. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
7. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
8. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Ak M; Bulut SD; Bozkurt A; Ozsahin A
Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
Dold M; Aigner M; Lanzenberger R; Kasper S
Fortschr Neurol Psychiatr; 2011 Aug; 79(8):453-66. PubMed ID: 21809258
[TBL] [Abstract][Full Text] [Related]
11. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
16. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
18. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
19. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]